Cell Therapy in Dilated Cardiomyopathy: Observational Study

Cell Therapy in Dilated Cardiomyopathy: A Safety and Feasibility Study Using Autologous Bone Marrow Mononuclear Cells

Using bone marrow mononuclear cell in 24 patients with Idiopathic dilated cardiomyopathy

Patients with Idiopathic dilated cardiomyopathy class II to IV NYHA with ejection fraction <35% were selected for phase I clinical trial of bone marrow mononuclear cell delivery in the coronary arteries and followed for 6 months

Inclusion Criteria:

• Diagnosis of idiopathic dilated cardiomyopathy
• Optimized therapy and for idiopathic dilated cardiomyopathy
• Left ventricular ejection fraction (Simpson) < 35%
• Peak oxygen consumption (VO2 peak) < 16 mL.kg-1min-1
• Functional classes II-IV of the NYHA

Exclusion Criteria:

• dilated cardiopathies of ischemic or chagasic origin
• primary valve disease
• excessive use of alcohol or illicit drugs
• pregnancy
• ventricular arrhythmias
• any co-morbidity with impact on survival